Now available on demand. Sign up to view
Harnessing the therapeutic potential of adoptively transferred cells
Originally aired; June 22, 2017
In this webcast Dr. Chapuis will describe how her research group has been pursuing adoptive transfer studies in humans with both non- and gene-modified T cells expressing tumor-specific TCRs for a broad range of targets. She will provide an overview of targeting strategies employed by her group, which have included both self-antigens and oncogenic viruses. She will discuss how they have used cutting-edge technologies, such as the 10x Genomics Chromium System, to help elucidate the reasons for success and failure of adoptive transfer in clinical research subjects and how using these technologies can accelerate development of more effective T cell therapies.
Specifically, Dr. Chapuis has been looking at Merkel cell carcinoma (MCC), a rare form of skin cancer that is most often the result of a virus called Merkel cell polyomavirus. Chapuis will review her investigation of how the cancer responds to T-cell immunotherapy over time, using scRNAseq to track changes in cell composition over the course of different rounds of treatment. Lastly, Dr. Chapuis will provide a future perspective on how these, and other new approaches, will help to develop new and improved immunotherapies for treating MCC.Webcast sponsor retains sole responsibility for content.